Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study

Phase 2 Recruiting 20 enrolled Tianjin Medical University Cancer Institute and Hospital

NaSingle-groupOpen-labelTreatment

Summary

Evaluation of the efficacy and safety of adding rituximab after failure of target immunotherapy in the Posterior treatment of advanced hepatocellular carcinoma

Timeline

Start: 2024-03-20
Primary completion: 2025-12-31
Completion: 2026-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous

Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study

Summary

Timeline

Drugs

Indications